Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII
- PMID: 21880112
- DOI: 10.1111/j.1538-7836.2011.04496.x
Best evidence on B-domain deletion and the immunogenicity of recombinant factor VIII
Comment in
-
Factor VIII inhibitors in previously treated hemophilic patients.J Thromb Haemost. 2011 Nov;9(11):2328-9. doi: 10.1111/j.1538-7836.2011.04510.x. J Thromb Haemost. 2011. PMID: 21929691 No abstract available.
Comment on
-
Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study.J Thromb Haemost. 2010 Jan;8(1):83-9. doi: 10.1111/j.1538-7836.2009.03650.x. Epub 2009 Oct 11. J Thromb Haemost. 2010. PMID: 19817995 Clinical Trial.
-
Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies.J Thromb Haemost. 2011 Nov;9(11):2180-92. doi: 10.1111/j.1538-7836.2011.04472.x. J Thromb Haemost. 2011. PMID: 21848690
-
Concentrate-related inhibitor risk: is a difference always real?J Thromb Haemost. 2011 Nov;9(11):2176-9. doi: 10.1111/j.1538-7836.2011.04480.x. J Thromb Haemost. 2011. PMID: 21854537 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
